Spyre Therapeutics, Inc. (SYRE)
(Delayed Data from NSDQ)
$37.80 USD
0.00 (0.00%)
Updated May 17, 2024 04:00 PM ET
After-Market: $37.85 +0.05 (0.13%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SYRE 37.80 0.00(0.00%)
Will SYRE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SYRE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SYRE
Here's What Could Help Spyre Therapeutics (SYRE) Maintain Its Recent Price Strength
Here's Why Spyre Therapeutics (SYRE) Could be Great Choice for a Bottom Fisher
SYRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SYRE
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
Spyre Therapeutics Expands Portfolio and Strengthens Leadership
Positive Outlook on Spyre Therapeutics’ IBD Pipeline and Financial Stability
Buy Rating Affirmed on Spyre Therapeutics as SPY001 Shows Promise Over Market Leader
Buy Rating Affirmed: Spyre Therapeutics’ Promising Pipeline and Expert Team Drive Positive Outlook